ZEVRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.03 USD | -2.52% |
|
+5.89% | -23.21% |
| 08/05 | Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M | MT |
| 08/05 | Transcript : Zevra Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12.6 | 48.32 | 307.6 | 158.4 | 271.7 | 215.9 | - | - |
| Enterprise Value (EV) 1 | 12.6 | 48.32 | 307.6 | 55.53 | 271.7 | 232.7 | 230.7 | 191.2 |
| P/E ratio | -0.46 x | -3.49 x | -4.13 x | -3.83 x | -5.04 x | -3.2 x | -17.6 x | 6.17 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.98 x | 3.64 x | 10.7 x | 15.1 x | 9.9 x | 7.35 x | 2.33 x | 1.32 x |
| EV / Revenue | 0.98 x | 3.64 x | 10.7 x | 5.31 x | 9.9 x | 7.92 x | 2.49 x | 1.17 x |
| EV / EBITDA | - | - | - | -1.34 x | - | -4.69 x | -20.2 x | 3.82 x |
| EV / FCF | - | - | - | -2.95 x | - | -5.57 x | -24.3 x | 6.73 x |
| FCF Yield | - | - | - | -33.9% | - | -18% | -4.12% | 14.8% |
| Price to Book | - | - | - | 1.84 x | - | 30.4 x | -73.7 x | 6.88 x |
| Nbr of stocks (in thousands) | 2,076 | 4,315 | 35,319 | 34,505 | 41,485 | 41,850 | - | - |
| Reference price 2 | 6.069 | 11.20 | 8.710 | 4.590 | 6.550 | 5.160 | 5.160 | 5.160 |
| Announcement Date | 28/02/20 | 11/03/21 | 30/03/22 | 07/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.84 | 13.29 | 28.65 | 10.46 | 27.46 | 29.37 | 92.78 | 163 |
| EBITDA 1 | - | - | - | -41.56 | - | -49.6 | -11.4 | 50 |
| EBIT 1 | -20.34 | -5.609 | 7.729 | -42.5 | -49.6 | -62.61 | -5.01 | 51.33 |
| Operating Margin | -158.4% | -42.21% | 26.98% | -406.44% | -180.63% | -213.16% | -5.4% | 31.49% |
| Earnings before Tax (EBT) 1 | -24.52 | -12.79 | -8.521 | -42.33 | -46.05 | -66.59 | -7.303 | 50.59 |
| Net income 1 | -24.54 | -12.76 | -62.9 | -41.54 | -46.05 | -66.56 | -7.303 | 49.14 |
| Net margin | -191.17% | -96.03% | -219.54% | -397.24% | -167.69% | -226.62% | -7.87% | 30.14% |
| EPS 2 | -13.28 | -3.210 | -2.110 | -1.200 | -1.300 | -1.614 | -0.2940 | 0.8367 |
| Free Cash Flow 1 | - | - | - | -18.81 | - | -41.8 | -9.5 | 28.4 |
| FCF margin | - | - | - | -179.86% | - | -142.32% | -10.24% | 17.42% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 56.8% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 57.79% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 28/02/20 | 11/03/21 | 30/03/22 | 07/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.965 | 2.582 | 3.965 | 1.3 | 2.874 | 2.319 | 2.879 | 8.47 | 2.895 | 13.22 | 3.425 | 4.81 | 5.846 | 17.99 | 13.73 |
| EBITDA 1 | - | - | - | - | -6.228 | -8.953 | -12.84 | -6.567 | -15.3 | - | -20.4 | -16 | -13.9 | 0.6 | - |
| EBIT 1 | -2.222 | -2.842 | -1.859 | -24.77 | -6.626 | -9.253 | -12.92 | -6.645 | -15.36 | -14.67 | -20.49 | -17.33 | -16.8 | -14.35 | - |
| Operating Margin | -113.08% | -110.07% | -46.89% | -1,905.15% | -230.55% | -399.01% | -448.91% | -78.45% | -530.71% | -111% | -598.13% | -360.35% | -287.41% | -79.75% | - |
| Earnings before Tax (EBT) 1 | -1.759 | -2.669 | -1.868 | -24.76 | -6.649 | -9.055 | -11.87 | -5.158 | -13.87 | -15.15 | -16.69 | -19.04 | -18.89 | -15.03 | - |
| Net income 1 | -1.759 | -2.703 | -1.864 | -24.04 | -6.616 | -9.021 | -11.77 | -5.084 | -14.04 | -15.15 | -16.62 | -19.04 | -18.89 | -15.03 | - |
| Net margin | -89.52% | -104.69% | -47.01% | -1,849.38% | -230.2% | -389% | -408.72% | -60.02% | -485.15% | -114.65% | -485.31% | -395.75% | -323.1% | -83.53% | - |
| EPS 2 | -0.0500 | -0.0800 | -0.0500 | -0.7000 | -0.1900 | -0.2600 | -0.3400 | -0.1500 | -0.4000 | -0.4000 | -0.4000 | -0.4475 | -0.4425 | -0.1450 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/11/21 | 30/03/22 | 12/05/22 | 11/08/22 | 09/11/22 | 07/03/23 | 15/05/23 | 14/08/23 | 07/11/23 | 28/03/24 | 08/05/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 16.8 | 14.8 | - |
| Net Cash position 1 | - | - | - | 103 | - | - | - | 24.7 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.3387 x | -1.298 x | - |
| Free Cash Flow 1 | - | - | - | -18.8 | - | -41.8 | -9.5 | 28.4 |
| ROE (net income / shareholders' equity) | - | - | - | -39% | - | -172% | -934% | 191% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 2.490 | - | 0.1700 | -0.0700 | 0.7500 |
| Cash Flow per Share 2 | - | - | - | -0.5400 | - | -0.6900 | 0.1100 | 0.7600 |
| Capex 1 | - | - | - | 0.09 | - | 2.55 | 1.78 | 2.55 |
| Capex / Sales | - | - | - | 0.89% | - | 8.68% | 1.92% | 1.56% |
| Announcement Date | 28/02/20 | 11/03/21 | 30/03/22 | 07/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.16
USD
Average target price
19
USD
Spread / Average Target
+268.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.21% | 216M | |
| +8.05% | 72.03B | |
| -11.95% | 5.14B | |
| +51.87% | 4.6B | |
| +3.92% | 3.96B | |
| -14.26% | 2.5B | |
| +20.42% | 2.43B | |
| -23.94% | 2.32B | |
| +20.02% | 2.18B | |
| +3.66% | 1.72B |
- Stock Market
- Equities
- ZVRA Stock
- Financials Zevra Therapeutics, Inc.